DSM and Firmenich confirm leadership team for proposed combined company DSM-Firmenich
|
HEERLEN, Netherlands and GENEVA, June 13, 2022 /PRNewswire/ -- DSM and Firmenich today jointly announce the future leadership team for DSM-Firmenich, building on the previously announced intended merger of the two companies that will establish the leading creation and innovation partner in nutrition, beauty and well-being.
The new company's Executive Committee will have a balanced team of talented individuals drawn from both DSM and Firmenich and representing the diversity, skillset, and ambitions of the combined company. The existing executive management teams of DSM and Firmenich will remain unchanged until the completion of the merger, which is expected ultimately in the first half of 2023. Each company remains committed to driving the ongoing performance of their respective businesses until then and to the subsequent successful handover of responsibilities wherever relevant.
The future Executive Committee of DSM-Firmenich will consist of:
Geraldine Matchett and Dimitri de Vreeze, as previously confirmed, will be Co-CEOs. Currently Co-CEOs of DSM, they will continue to hold additional CFO (Geraldine) and COO (Dimitri) responsibilities respectively for the future combined company. Geraldine joined DSM as CFO and Managing Board member in 2014. A Swiss-French-British national, she had been Global Chief Financial Officer and member of the Operations Council of the SGS Group since 2010, during which she was voted Switzerland's CFO of the year for large companies. Dimitri, a Dutch national, began working at DSM in 1990 and held a series of leadership roles before being named Young Captain of the Year in the Netherlands – a countrywide leadership talent program – in 2006. He was later appointed to DSM's Managing Board in 2013. Geraldine and Dimitri became Co-CEOs of DSM in 2020.
It has also been previously announced that Emmanuel Butstraen will be Chief Integration Officer, overseeing the merger of these two iconic companies. Emmanuel, a French national, joined Firmenich in 2018 as President of Taste & Beyond to drive the transformation of that division. He had spent the previous ten years leading businesses at Solvay, including the last nine years on the company's Management Committee. Prior to this he spent 17 years with BASF.
DSM-Firmenich will bring together a world-class foundation in science and technology with deep expertise across a global network of 15 R&D facilities, which will be led by Dr. Sarah Reisinger. Sarah, a US national, holds a Ph.D. in Microbiology from the University of California, Berkeley and has extensive experience in biology and related fields, previously serving in leadership roles at Ginkgo Bioworks and Amyris. She joined Firmenich in 2018 to lead the company's biotechnology and process engineering teams before taking on her current position of Chief Research Officer in 2021.
DSM-Firmenich will have four high-performing and complementary businesses, all with pioneering, leadership positions and each led by a member of the future Executive Committee.
Perfumery & Beauty, incorporating Firmenich's Fragrance and Ingredients divisions and DSM's Personal Care & Aroma business, will be led by Ilaria Resta, who is currently Firmenich's President of Perfumery. Ilaria, an Italian-Swiss national, is an internationally awarded industry leader who joined Firmenich in 2020 after two decades with Procter & Gamble during which she was responsible for building some of the world's leading home and personal care brands.
Patrick Niels, DSM's Executive Vice President Food & Beverage, will lead the combined Food & Beverage/Taste & Beyond business in establishing a global-scale partner for the industry with extensive capabilities in taste, nutrition and functionality. Patrick, a Dutch-US national, began his career at Gist-Brocades in 1991, which was acquired by DSM in 1998. He has since held various leadership roles across the company in different businesses and in various regions including almost nine years in the US where, amongst others, he was responsible for both North and South America.
DSM's Executive Vice President Health, Nutrition & Care, Philip Eykerman, will continue to lead this business' development of customized quality end-to-end solutions that support the health of people at every life stage. Philip, a Belgian national, left McKinsey & Company in 2011 to oversee DSM's corporate strategy and M&A as Executive Vice President Corporate Strategy & Acquisitions. Since 2020, he has been responsible for all of DSM's activities in human nutrition and health, as well as M&A across the company.
Ivo Lansbergen, who was appointed DSM's Executive Vice President for Animal Health & Nutrition in 2019, will continue to lead this business in developing solutions to alleviate pressure on the planet's finite natural resources while satisfying the increasing demand for protein. Ivo, a Dutch national, has been with DSM since 1997 during which time he has held various senior positions in different DSM businesses in both Europe and Asia.
The success of both DSM and Firmenich is based on each company's passionate, talented and diverse workforce. Mieke Van de Capelle, currently Firmenich's Chief Human Resources Officer, will lead in creating an engaging culture that continues to put its people first. Mieke, a Belgian national, combines twenty years of business acumen and a deep understanding of people and culture strategies within global innovation-driven organizations such as Sara Lee Corporation and Perfetti van Melle. She joined Firmenich in 2016 and, under her leadership, Firmenich became one of only seven companies in the world to obtain the EDGE global certification for gender equality.
Recognizing the scope and global reach of the new DSM-Firmenich company, Jane Sinclair, presently Firmenich's General Counsel and Head of Legal and Compliance, will complete the new Executive Committee. An Australian national, Jane brings more than thirty years' experience of corporate law, regulation and compliance, business ethics, intellectual property and beyond in both emerging and mature markets. With her commitment to responsible business, the company's leadership in environmental, safety and regulatory stewardship has been recognized globally, including a CDP "Triple A" score for four consecutive years. Prior to joining Firmenich in 2015, Jane held various senior roles at companies including Abbott, AbbVie, and The Coca-Cola Company.
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs of DSM, commented: "We are appreciative of the support from all the leaders on the current executive management teams of DSM and Firmenich as everyone is fully committed to the successful integration of these great companies. They have laid the foundations from which DSM-Firmenich will be able to make a major difference for our customers, and ultimately for people and the planet. This talented team draws on the incredible expertise of both organizations and our future Executive Committee will be an incredibly strong joint leadership team with proven track records of strategic execution and value creation for all stakeholders. By coming together, we will establish a company where anyone, anywhere, wishing to make a positive impact should aspire to work."
Gilbert Ghostine, who will retire from his position as CEO of Firmenich upon completion of the merger, commented: "There is a tremendous amount of talent and skill in both organizations and this executive team is perfectly placed to bring together our two culturally aligned and iconic businesses. I am confident that through this team, DSM-Firmenich has the right balance of experience, capabilities and skills to provide compelling opportunities for our people. The leaders we are announcing today are all highly accomplished and will ensure we create a global leader capable of bringing breakthrough purpose-led innovation and technologies to our customers."
Please visit www.creator-innovator.com for additional material on the proposed transaction and DSM-Firmenich.
Capital Markets Day
DSM and Firmenich are hosting a joint Capital Markets Day for institutional investors and equity analysts today in Paris, France.
Here will be offered a deeper understanding of Firmenich's businesses; and presenting DSM-Firmenich, outlining its key value drivers, demonstrating how the complementary nature of DSM and Firmenich can enable enhanced innovation and co-creation with their customers, and through this, increase returns and deliver long-term sustainable growth and shareholder value.
The event will start at 13.30 CEST. A live webcast of the presentations and the Q&A session can be accessed here.
About Firmenich
Firmenich is the world's largest privately-owned fragrance and taste company and has been family-owned for 127 years. The Swiss company specializes in perfumes, flavors, and ingredients and is renowned for its world-class research as well as leadership in sustainability.
About DSM
DSM has transformed during its 150+ year history into today's health, nutrition & bioscience global leader. The Dutch-Swiss company specializes in nutritional ingredients for food and feed with proven world-leading bioscience capabilities and an international network of high-quality manufacturing sites that underpin a business model of global products, local solutions and personalization and precision.
For more information
DSM media enquiries: FTI Consulting LLP Edward Bridges / Alex Le May Email: scdsm@fticonsulting.com Telephone: +44 20 3727 1017 |
Firmenich media enquiries: Brunswick Group Joseph Chi Lo / Edward Brown Email: firmenich@brunswickgroup.com Telephone: +44 20 7404 5959 |
DSM Investor Relations enquiries: Dave Huizing Email: investor.relations@dsm.com Telephone: +31 45 578 2864 |
Firmenich Investor Relations enquiries: Diego Chantrain Email: investor_relations@firmenich.com Telephone: +41 75 429 45 93 |
|
NO OFFERING IS BEING MADE TO ANY PERSON IN ANY JURISDICTION. THIS ANNOUNCEMENT MAY NOT BE USED FOR, OR IN CONNECTION WITH, AND DOES NOT CONSTITUTE, OR FORM PART OF, AN OFFER BY, OR INVITATION BY OR ON BEHALF OF, DSM, FIRMENICH OR ANY REPRESENTATIVE OF DSM OR FIRMENICH, TO PURCHASE ANY SECURITIES OR AN OFFER TO SELL OR ISSUE, OR THE SOLICITATION TO BUY SECURITIES BY ANY PERSON IN ANY JURISDICTION. NO ACTION HAS BEEN OR WILL BE TAKEN IN ANY JURISDICTION BY DSM OR FIRMENICH THAT WOULD PERMIT AN OFFERING OF THE ORDINARY SHARES OR POSSESSION OR DISTRIBUTION OF A PROSPECTUS IN ANY JURISDICTION, EXCEPT TO THE EXTENT EXPLICITLY DISCLOSED BY DSM OR FIRMENICH. |
This announcement is for information purposes only it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, DSM, Firmenich and DSM-Firmenich do not guarantee its accuracy or completeness and DSM, Firmenich and DSM-Firmenich will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation and DSM, Firmenich and DSM-Firmenich expressly disclaim liability for any errors or omissions. |
This announcement contains materials produced by third parties and this content has been created solely by such third parties with no input from the DSM Group or Firmenich International SA. It is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation on the DSM Group or Firmenich International SA. All proprietary rights and interest in or connected with this announcement shall vest in the DSM Group or Firmenich International SA, as the case may be. No part of it may be redistributed or reproduced without the prior written permission of the DSM Group and Firmenich Group. All proprietary rights and interest in or connected with this publication shall vest in DSM or Firmenich, as the case may be. This announcement speaks only as of this date. |
Additional information for US holders |
The securities referred to herein and to be issued pursuant to the proposed Offer have not been, and are not presently intended to be, registered under the Securities Act of 1933, as amended (the "Securities Act") or under any laws or with any securities regulatory authority of any state, district or other jurisdiction, of the United States, and unless so registered may only be offered or sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state and other securities laws. There is not presently expected to be any public offer of any securities in the United States. The information contained herein does not constitute an offer to sell or solicitation of an offer to buy any securities in the United States. Further details of which US holders are eligible to receive the securities referred to herein, and the procedural steps required to be taken by such persons to so receive such securities, as well as the procedures for those US holders who do not so qualify to receive such securities (if any), will be set forth in the Offering Circular. |
Neither the U.S. Securities and Exchange Commission (SEC) nor any US state securities commission has approved or disapproved of the securities referred to herein to be issued in connection with the proposed Offer or any related corporate transaction, or determined if the information contained herein or in the Offering Circular to be prepared in connection with the proposed exchange offer is accurate or complete. Any representation to the contrary is a criminal offence in the United States. |
The securities referred to herein have not been and are not presently expected to be listed on any US securities exchange or quoted on any inter-dealer quotation system in the United States. None of DSM-Firmenich, DSM or Firmenich presently intends to take any action to facilitate a market in such securities in the United States. |
Financial statements, and all financial information that is included in the information contained herein or that may be included in the Offering Circular and any other documents relating to the securities referred to herein, have been or will be prepared in accordance with International Financial Reporting Standards (IFRS) or other reporting standards or accounting practice which may not be comparable to financial statements of companies in the United States or other companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States (US GAAP). |
It may be difficult for US holders to enforce their rights and claims arising out of the US federal securities laws, since DSM is incorporated under the laws of the Netherlands and DSM-Firmenich and Firmenich are incorporated under the laws of Switzerland, and in each case the majority or all of their respective officers and directors are residents of non-US jurisdictions. Judgments of US courts are generally not enforceable in either the Netherlands or Switzerland. US holders may not be able to sue a non-US company or its officers or directors in a non-US court for violations of US securities laws. Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to a US court's judgment. In addition, original actions, or actions for the enforcement of judgments of US courts, based on the civil liability provisions of the US federal securities laws, may not be enforceable in the Netherlands or Switzerland. |
Information Regarding Forward-Looking Statements. |
Financial Information. Financial objectives are internal objectives of DSM, Firmenich and the Combined Group to measure its operational performance and should not be read as indicating that DSM, Firmenich or the Combined Group is targeting such metrics for any particular financial year. The ability of DSM, Firmenich and the Combined Group to achieve these financial objectives is inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of DSM, Firmenich and the Combined Group, and upon assumptions with respect to future business decisions that are subject to change. As a result, the actual results of DSM, Firmenich and the Combined Group may vary from these financial objectives, and those variations may be material. |
Transaction conditions. Completion of the Proposed Combination is subject to the satisfaction of a number of conditions as more fully described in this announcement. Consequently, there can be no certainty that completion of the Proposed Combination will be forthcoming. |
DSM refers to DSM N.V. and the DSM Group refers to DSM and its subsidiaries. Firmenich refers to Firmenich International SA and its subsidiaries. The Combined Group refers to DSM-Firmenich and its subsidiaries following completion of the Proposed Combination (including the DSM Group and Firmenich International SA). |
Logo - https://mma.prnewswire.com/media/1829134/DSM_Firmenich_Logo.jpg
